Plasma Fractionation Market Size, Share, and Trends 2024 to 2033

Plasma Fractionation Market Size to Exceed USD 74.07 Billion by 2033

The global plasma fractionation market size was valued at USD 33.31 billion in 2023 and is anticipated to reach around USD 74.07 billion by 2033, growing at a CAGR of 8.32% from 2024 to 2033. The growing prevalence of genetic diseases across the world is driving the growth of the plasma fractionation market.

Plasma Fractionation Market Key Takeaways

• The North America plasma fractionation market size accounted for USD 18.32 billion in 2023 and is expected to attain around USD 41.11 billion by 2033, poised to grow at a CAGR of 8.41% between 2024 and 2033.
• North America led the market with the largest revenue share of 55% in 2023.
• Asia Pacific is expected to witness the fastest rate of growth in the market during the forecast period.
• By method, the centrifugation segment has contributed more than 35% of revenue share in 2023.
• By method, the chromatography will grow rapidly during the forecast period.
• By product, the immunoglobins segment dominated the market in 2023.
• By product, the coagulation factors segment is projected to witness the fastest growth during the forecast period.
• By application, the neurology segment dominated the market in 2023.
• By application, the oncology segment will grow at a considerable rate in the market during the forecast period.
• By end use, the hospitals & clinics segment has held a major revenue share of 52% in 2023.
• By end use, the clinical research segment is projected to grow rapidly in the market during the forecast period.

U.S. Plasma Fractionation Market Size and Growth 2024 to 2033

The U.S. plasma fractionation market size was estimated at USD 12.82 billion in 2023 and is predicted to be worth around USD 28.98 billion by 2033 with a CAGR of 8.49% from 2024 to 2033.

North America led the global plasma fractionation market in 2023. The growth of this region is mainly driven by the growing number of plasma research institutes along with a rising number of startup companies related to plasma medicines. Moreover, the growing cases of rare diseases in countries such as Canada and the U.S. have also increased the demand for plasma medicines, thereby driving the market growth of the market. In addition, the growing prevalence of nerve and bone-related issues has also increased the demand for plasma therapies, which, in turn, drives the market growth. Also, the presence of plasma companies such as Baxter, LFB Plasma, Pall Corporation, ADMA Biologics, Inc., and some others also drives the market growth.

• In September 2022, Grifols S.A. announced a business agreement with Canadian Blood Services. This agreement was made to open a new plasma fractionation facility in Montreal, Canada, that will help in the production of essential plasma-protein therapies and immunoglobulin (Ig) medicines for the treatment of a wide range of immunodeficiencies and some other diseases.
• According to a study conducted by the National Institutes of Health (NIH), the number of rare diseases reached 7000 among the people of the U.S. It also stated that 1 in every ten people in the U.S. suffered from rare diseases.
• According to the International Osteoporosis Foundation, there are around 300,000 hip fractures in the U.S. every year, out of which 25% die due to such fractures.

Asia Pacific is expected to witness the fastest rate of growth in the plasma fractionation market during the forecast period. The growth of this region is mainly driven by scientific developments and advancements in the healthcare sector in countries such as India, Japan, and China. Also, the rising initiatives from the public and private sectors for research & development related to plasma therapeutics have also boosted the market growth. Moreover, an increase in government initiatives aimed at opening plasma centers also fosters market growth. Furthermore, the presence of biopharma companies such as Grifols, Octapharma, Sanquin, CSL, Eden Biologics, and some others is also driving the growth of the market.

• In March 2023, Takeda Pharmaceutical Company Limited announced that it would invest around 100 billion yen in building a new plasma therapy plant in Osaka, Japan. The facility will be constructed according to global manufacturing standards along with the latest automation and advanced digital technologies for the purification, filling, and fractionation of plasma products.

Plasma Fractionation Market Overview

The plasma fractionation industry has experienced rapid developments due to advancements in healthcare sectors. Plasma fractionation is a down-streaming method that deals with separating different components of blood plasma. This process is used to convert human plasma into medicines and therapies for the treatment of different diseases. It uses various separation processes such as depth filtration, precipitation, centrifugation, and chromatography. The application of plasma fractionation has increased rapidly in various domains such as neurology, immunology, hematology, and some others due to the higher efficacy of plasma therapies than conventional medicines.

This plasma fractionation market is fragmented, with the presence of small and large market players. These market players are actively engaged in research and development activities related to plasma fractionation. Some of the most prominent market players include Boccard, Grifols, S.A., Hemarus Therapeutics Limited, ADMA Biologics, Bio Products Laboratory Ltd., Intas Pharmaceuticals Limited, LFB S.A., Merck Group, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., SK Plasma Co. Ltd, Virchow Biotech Private Limited and some others.

• In March 2024, ADMA Biologics announced that the United States Food and Drug Administration (FDA) approved the Asceniv and Bivigam plasma therapies. These therapies will be manufactured in an FDA-licensed plasma fractionation facility in Boca Raton, Florida, U.S.

Plasma Fractionation Market Growth Factors

• The growing demand for plasma-derived medicinal products (PDMPs) has boosted the plasma fractionation market growth.
• The rising awareness related to the diagnosis and treatment of auto-immune diseases has also driven the growth of the plasma fractionation market.
• The technological advancements in medical sciences have also boosted the market growth.
• The rise in the geriatric population suffering from rare diseases has increased the demand for plasma fractionation.
• The growing application of plasma fractionation in therapeutic use is driving the growth of the plasma fractionation market.
• The increasing prevalence of heart diseases and alpha-1 antitrypsin deficiency (AATD) has also fostered the market growth.
• The Government initiatives related to the development of healthcare infrastructure propel the growth of the plasma fractionation market.

Plasma Fractionation Market Scope

Plasma Fractionation Market Dynamics

Driver: Growing incidences of von willebrand's disease

The rising prevalence of Von Willebrand's disease has increased the demand for plasma therapy. Plasma therapies are found to be highly effective for treating Von Willebrand's disease as they help in blood clots in different parts of the human body. This, in turn, drives the growth of the plasma fractionation market. Also, several plasma-based therapies are approved by government organizations for the treatment of Von Willebrand's disease.

• According to a study conducted by Centres for Disease Control and Prevention (CDC), Von Willebrand disease (VWD) occurs in the same frequency among men and women; around 1% of the overall population of the world suffers from this genetic disorder.
• In December 2023, Octapharma announced that the U.S. Food and Drug Administration (FDA) had approved wilate. This medication is suitable for prophylactic treatment of all forms of von Willebrand disease (VWD).

Restrain: High cost and unavailability of high-quality plasma

There have been several developments in the plasma fractionation industry in recent times. The research and development activities related to plasma-based products come with a high cost. Also, the availability of suitable plasma is very low, and plasma companies import plasma from different parts of the world, which is very costly. Thus, higher costs associated with plasma product manufacturing are expected to restrain the growth of the plasma fractionation market.

Opportunity: Rising investments to develop plasma fractionation

The plasma therapy industry has grown rapidly in recent times due to the rising number of rare diseases across the world. Several plasma therapy companies have started focussing on enhancing their plasma fractionation and collection capabilities. Also, some plasma product companies have started adopting strategies such as business expansions, acquisitions, and the inauguration of R&D facilities related to plasma therapeutics. Thus, growing investment related to plasma fractionation is expected to create ample growth opportunities for the plasma fractionation market players.

• In December 2022, CSL Limited invested 900 million USD in opening a new plasma fractionation facility in Australia. This plasma fractionation facility will help in the extraction of human plasma to treat patients suffering from immune system problems, hemophilia, burns, and other medical issues.

Method Insights

The centrifugation segment led the plasma fractionation market in 2023. The growth of this segment is driven by the growing application of this method for the extraction of cells from plasma. Moreover, centrifugation methods can facilitate the separation of red blood cells and white blood cells from one another or from platelets. Thus, the rising application of centrifugation for different applications boosts the growth of the market.

The chromatography will grow rapidly during the forecast period. The growth of this segment can be attributed to the growing application of chromatographic purification in the removal of plasma viruses, along with the rising use of industrial chromatography for plasma fractionation. Also, the rise in research and development activities related to the extraction of pure plasma along with albumin production has further driven the market growth. Moreover, the presence of High-performance liquid chromatography (HPLC) equipment companies such as Agilent Technologies. Welch Materials, Waters Corporation, Thermo Fisher Scientific, Waters Corporation, ArgusEye, Shimadzu Corporation, and PerkinElmer, Inc. also drive the market growth.

• In April 2024, Waters Corporation launched the ‘iS Bio HPLC System’. This HPLC system comes with MaxPeak High-Performance Surface (HPS) Technology that helps QC analysts of biopharma companies to derive pure products from any sample.

Product Insights

The immunoglobins segment dominated the plasma fractionation market in 2023. This segment is mainly driven by the rise in the number of patients suffering from melanoma and prostate cancer around the world. Also, several research and developments related to the innovation of immunoglobulin therapies, along with the rising application of immunoglobin in neurological disorders, are driving the market growth. Moreover, the presence of immunoglobins companies such as CSL Behring, Kedrion S.p.A., Takeda, Octapharma, Baxter International Inc., Biotest AG, and some others boosts the market growth.

• In January 2024, Takeda announced that the U.S. Food and Drug Administration (FDA) had approved Gammagard Liquid. It is an intravenous immunoglobulin (IVIG) therapy that can help to treat impairment and neuromuscular disability in adults.

The coagulation factors segment is projected to witness the fastest growth in the plasma fractionation market during the forecast period. The growth of this segment is mainly due to the growing application of plasma coagulation for stopping blood losses during endoscopy and treatment of gastrointestinal diseases. Moreover, the growing cases of sickle cell anemia have increased the demand for plasma coagulation, thereby driving the growth of the market.

• According to a recent study by the Centers for Disease Control and Prevention (CDCP), in May 2024, more than 100,000 people suffered from Sickle cell disease (SCD) in the United States in 2023.

Application Insights

The neurology segment dominated the plasma fractionation market in 2023. This segment is generally driven by the rise in the number of nerve patients across the world. Plasma-based medications are found to be highly effective against nervous disorders, which in turn boosts the market growth. Also, the research and advancements related to neurological sciences, along with the rising adoption of plasma therapies for the treatment of nerve problems, accelerate the growth of the market.

• According to the World Health Organisation (WHO), more than 3 billion people around the world suffer from neurological disorders.

The oncology segment will grow at a considerable rate in the plasma fractionation market during the forecast period. The growth of this segment is generally driven by the rise in government initiatives towards cancer along with the growing application of plasma therapies for treating cancer. Moreover, the growing prevalence of cancer around the world also drives the market growth. Also, the growing adoption of plasma-assisted cancer immunotherapy and the use of cold atmospheric plasma (CAP) for treating cancer patients has also boosted the growth of the market.

• According to the National Cancer Institute, more than 20 million new cancer cases were diagnosed, and 9.7 million people died due to cancer in 2022.

End-use Insights

The hospitals & clinics segment held the largest share of the plasma fractionation market in 2023. The growth of this segment is generally driven by the growing number of hospitals and clinics across the world. Also, growing advancements in hospital infrastructure for the treatment of auto-immune diseases drive the growth of the market. Moreover, the availability of experienced doctors in clinical settings has also increased the demand for plasma therapies for the treatment of cancer, heart diseases, and some others, thereby driving the market growth.

The clinical research segment is projected to grow rapidly in the plasma fractionation market during the forecast period. The growth of this segment can be attributed to the rising adoption of plasma therapy for the treatment of rare diseases. Moreover, rising research and development activities for the production of plasma-based therapeutics also drive the growth of the market.

Plasma Fractionation Market Recent Developments

• In December 2023, GC Biopharma announced that the Indonesian government approved the construction of a plasma fractionation plant in Jababeka Industrial Estate. This plant is expected to be operational in 2027 and will produce around 4000000 liters of plasma for medicinal use.
• In March 2023, CSL Limited opened a new plasma fractionation facility in Marburg, Germany. This manufacturing plant cost around 470 million USD and was opened with the aim of using human-donated plasma in useful medicines.

Plasma Fractionation Market Companies

• Grifols S.A.
• CSL Limited
• Takeda Pharmaceutical Company Limited
• Octapharma AG
• Kedrion S.p.A
• LFB S.A.
• Biotest AG
• Sanquin
• Bio Products Laboratory Ltd.
• Intas Pharmaceuticals Ltd

Segments Covered in the Report

By Product

• Albumin
• Immunoglobulins
  • Intravenous Immunoglobulins
  • Subcutaneous Immunoglobulins
  • Others
• Coagulation Factors
  • Factor viii
  • Factor ix
  • Von Willebrand Factor
  • Prothrombin Complex Concentrates
  • Fibrinogen Concentrates
  • Others
• Protease Inhibitors
• Others

By Method

• Centrifugation
• Depth Filtration
• Chromatography
• Others

By Application

• Neurology
• Hematology
• Oncology
• Immunology
• Pulmonology
• Others

By End-use

• Hospitals & Clinics
• Clinical Research
• Others

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa